Dr Alishah Suleman

Key Appointments:

• Former Principal Investigator, St Pancras Clinical Research

• Former ACCS Anaesthetics CT1, Birmingham Heartlands Hospital

• Former Clinical Fellow in Intensive Care, Croydon University Hospital

Years of Experience:

10+ years of clinical and research experience, including intensive care and specialised CNS trial delivery

Therapeutic Areas (CNS & Psychiatry):

Major Depressive Disorder (MDD), Treatment-Resistant Depression (TRD), Generalised Anxiety Disorder (GAD), PTSD, Post-Partum Depression, Cognitive Impairment, Early Alzheimer’s Disease, Dementia, Migraine, Chronic Pain

Drug Classes & Modalities:

Psychedelics (COMP360, CYB003, MM120), monoclonal antibodies, biologics, CNS small molecules, migraine therapeutics (Ategopant, Botox), cannabinoid-based agents, neuroplasticity agents, metabolic modulators, GLP-1 agonists, anti-inflammatory agents

Clinical Trials Experience:

• PI on 12 Phase II–III trials (psychiatry, migraine, Alzheimer’s, pain)
  Sub-Investigator on 18 trials, including psychedelic-assisted protocols

• Experience across Schedule 1 CNS compounds and psychiatric rating scales

• Led studies for AbbVie, AstraZeneca, Lilly, Lundbeck, GSK, Novo Nordisk, Compass, Cybin, MindMed, Transcend and more

• Delivered complex Alzheimer’s studies including CLARITY AD, AHEAD 345, LAKI and PROGRESS